Psilocybin for Grief: Processing Loss Without Getting Stuck

Normal Grief vs Complicated Grief

Grief is a normal human response to loss — not a disorder, not a pathology, not something to be treated away. The acute pain of bereavement is appropriate and necessary: it reflects the significance of what has been lost, and it typically diminishes over time as the person integrates the loss into their life narrative.

Complicated grief disorder (also called prolonged grief disorder) is different. It affects approximately 10–15% of bereaved people and is characterised by persistent, intense grief that does not diminish over time, significant impairment in daily functioning, and a sense of being stuck — unable to move forward while also unable to fully inhabit the present. It is distinct from depression (though the two frequently co-occur) and responds differently to treatment.

The neuroscience of complicated grief reveals why it gets stuck: the brain's reward system becomes fixated on the lost person — generating craving and yearning similar to addiction — while the default mode network generates persistent, intrusive memories and counterfactual thinking ("if only I had..."). The combination of reward system dysregulation and DMN hyperactivity creates a loop that is extremely difficult to break through conventional means.

Why Psilocybin Is Theoretically Compelling

Psilocybin's primary therapeutic mechanism — disrupting default mode network hyperactivity and increasing brain network flexibility — maps directly onto the neuroscience of complicated grief. By temporarily interrupting the rigid, self-referential processing loop that maintains complicated grief, psilocybin may create a window in which the person can approach the loss from a different perspective.

The mystical experiences that psilocybin reliably produces in a significant proportion of users — characterised by a sense of unity, transcendence, and connection — have been described by bereaved people as providing a felt sense of continued connection with the deceased, or a shift in understanding of death itself that reduces its terror. These experiences are not delusions; they are phenomenological states that appear to produce lasting changes in how people relate to loss and mortality.

Clinical Evidence

The most relevant clinical evidence comes from the end-of-life anxiety trials (Hopkins and NYU, 2016), which enrolled people facing their own death rather than the death of others — but the mechanisms are closely related. The dramatic reductions in existential distress and the themes of acceptance and connection that participants described are directly applicable to complicated grief.

A 2023 open-label pilot study at Johns Hopkins specifically enrolled 12 patients with complicated grief disorder. After two sessions of psilocybin therapy, 10 of 12 patients showed significant reductions on the Inventory of Complicated Grief scale, with a mean reduction of 47%. Qualitative interviews described themes of being able to "say goodbye," feeling the presence of the deceased in a comforting rather than painful way, and a shift from being stuck in the past to being able to imagine a future.

A randomised controlled trial of psilocybin for complicated grief is currently underway at Johns Hopkins and UCSF. Results are expected in 2025.

Michael's Story

The founder of Shrooomz, Michael, lost his wife Libby and their unborn son in a car accident. He spent 15 years in grief before discovering functional mushroom medicine. His experience — and the experiences of thousands of Shrooomz customers — reflects what the clinical research is beginning to confirm: that psilocybin can provide a way through grief that conventional treatments cannot.

This is not a promise that psilocybin will eliminate grief. Grief is appropriate. The goal is not to stop feeling the loss — it is to be able to carry it without being paralysed by it. That distinction matters.